Prophetic announced the launch of two consumer-facing ultrasonic neuromodulation devices designed to enhance dreaming: Dual at $449 (shipping Q4 2026) and Phase at $1,299 (shipping Q3 2027). Both pair EEG sensors with targeted focused ultrasound, and the company claims a 100x cost reduction over comparable research-grade ultrasound systems. Backed by BoxGroup and a16z's Scout Fund, the launch is among the first of its kind in the consumer space, though no peer-reviewed efficacy data has been published ahead of ship date.